Sarah Cannon Research Institute
Sarah Cannon Research Institute
Denver, Colorado, United States16 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) | Progressive Metastatic Castrate Resistant Prostate Cancer | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07206056 | |
| R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, adenoma, basal cell carcinoma, basal cell neoplasm, epithelial neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm, squamous cell carcinoma, squamous cell neoplasm | Recruiting | Phase 1 | 2026-09-18 | NCT06398418 | |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-11 | NCT05520567 | |
| A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract cancer, biliary tract disorder, neoplasm | Active, not recruiting | Phase 1 | 2026-09-02 | NCT03440450 | |
| A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, gastric cancer, gastric neoplasm, intestinal disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, rectal disorder, stomach disorder | Recruiting | Phase 1 | 2026-08-13 | NCT07066657 | |
| Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors | Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, liposarcoma, myxoid liposarcoma, neoplasm, sarcoma, synovial sarcoma | Active, not recruiting | Phase 2 | 2026-08-11 | NCT03967223 | |
| A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast cancer, breast disorder, breast neoplasm, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, intellectual disability, X-linked, with or without seizures, ARX-related, intestinal disorder, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, prostate cancer, prostate disorder, rectal disorder, skin disorder, uterine disorder | Active, not recruiting | Phase 1 | 2026-07-13 | NCT05787587 | |
| A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Solid Tumor, Adult | Recruiting | Phase 1 / Phase 2 | 2026-06-25 | NCT04219254 | |
| Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Liver Neoplasms, Male Urogenital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, benign urinary system neoplasm, biliary tract cancer, biliary tract disorder, breast cancer, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, cervix disorder, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, esophageal cancer, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, gastroesophageal cancer, head and neck cancer, intestinal disorder, kidney cancer, kidney disorder, liver disorder, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, malignant colon neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, non-small cell lung carcinoma, pancreas disorder, pancreatic neoplasm, prostate cancer, prostate disorder, rectal cancer, rectal disorder, rectal neoplasm, respiratory system disorder, respiratory tract neoplasm, skin disorder, stomach disorder, thyroid gland disorder, thyroid tumor, urinary system disorder, uterine disorder | Recruiting | Phase 1 / Phase 2 | 2026-05-06 | NCT06239194 | |
| A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Solid Tumors | Recruiting | Phase 1 | 2026-04-17 | NCT06307795 | |
| QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations | Advanced Solid Tumors | Active, not recruiting | Phase 1 | 2026-03-02 | NCT06715124 | |
| A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, astrocytoma (excluding glioblastoma), brain cancer, brain disorder, breast cancer, breast disorder, breast neoplasm, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioblastoma, glioma, male reproductive organ cancer, male reproductive system disorder, melanocytic neoplasm, melanoma, metastatic melanoma, metastatic prostate carcinoma, neoplasm, nervous system disorder, neuroendocrine neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate disorder, skin disorder, skin neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-02-09 | NCT04478279 | |
| Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | Advanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C Mutation | Active, not recruiting | Phase 1 | 2025-10-22 | NCT04185883 | |
| First in Human Study of TORL-3-600 in Participants With Advanced Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Phase 1 | 2025-10-10 | NCT05948826 | |
| A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, pancreatic adenocarcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, susceptibility to familial cutaneous melanoma | Active, not recruiting | Phase 1 / Phase 2 | 2025-09-02 | NCT05585320 | |
| AMT-116 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 | 2025-08-17 | NCT05725291 |